צמיחת הכנסות שנתית ב-12 החודשים האחרונים: Absci Bio (ABSI)

Absci growth relies on expanding partnerships with pharma behemoths and the validation of AI models. Year-over-year sales volatility over a rolling 12-month period demonstrates revenue dynamics, where the current level equals -47.70. Profitability is based on future royalties and milestones. The company's prospects depend on the accuracy of protein synthesis algorithms and the overall volume of investment in the biotechnology sector.

This indicator calculates the percentage change in total revenue over the last twelve months relative to the same period last year, reflecting the business's sensitivity to capital inflows. Analyzing the TTM annual sales growth rate allows for an assessment of how Absci (ABSI) scales its AI platforms through strategic partnerships with pharma behemoths, where accelerating expansion rates serve as a signal of either market saturation or a technological breakthrough.